OPKO Health and Entera Bio Expand Partnership to Advance Oral PTH Tablet.

OPKO Health and Entera Bio have expanded their partnership to develop a first-in-class oral long-acting parathyroid hormone (PTH) tablet for patients with hypoparathyroidism. The companies aim to file an IND application in late 2026 and have accelerated the program. This is the third successful combination of Entera's oral peptide N-Tab platform with OPKO's advanced protein chemistry capabilities. Additionally, injectable and oral oxyntomodulin for metabolic and fibrotic disorders are advancing, with initial Phase 1 data expected in late 2026. Industry veteran Steve Rubin has joined Entera's board.